network member

Columbia University Irving Medical Center

New York, NY

About Network Member

Website: Columbia University Irving Medical Center

https://www.cuimc.columbia.edu

Currently Enrolling

HCRN-GU16-243

PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243

Noah M. Hahn

Cancer areas:Bladder Urothelial Carcinoma

Columbia University Irving Medical Center

Fox Chase Cancer Center

Fred & Pamela Buffett Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

University of Iowa Holden Comprehensive Cancer Center

See clinicaltrials.gov

Currently Enrolling

HCRN-GU20-436

NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations

Cancer areas:Prostate

Columbia University Irving Medical Center

Memorial Sloan Kettering Cancer Center

Moores Cancer Center at UC San Diego Health

Penn Medicine Abramson Cancer Center

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

See clinicaltrials.gov

Currently Enrolling

HCRN-GU22-587

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)

Cancer areas:Kidney

Beth Israel Deaconess Medical Center

Columbia University Irving Medical Center

Dana-Farber Cancer Institute

Georgetown Lombardi Comprehensive Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

John Theurer Cancer Center at Hackensack Meridian Health

Moores Cancer Center at UC San Diego Health

Penn Medicine Abramson Cancer Center

The Ohio State University

UT Southwestern Harold C. Simmons Comprehensive Cancer Center

Weill Cornell Medicine

Winship Cancer Institute of Emory University

Yale Cancer Center

See clinicaltrials.gov

Enrollment Closed

HCRN-GU16-260

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Michael B. Atkins

Cancer areas:Kidney

Beth Israel Deaconess Medical Center

Cleveland Clinic Cancer Center

Columbia University Irving Medical Center

Fox Chase Cancer Center

Georgetown Lombardi Comprehensive Cancer Center

Penn Medicine Abramson Cancer Center

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

University of Illinois Cancer Center

UT Southwestern Harold C. Simmons Comprehensive Cancer Center

Winship Cancer Institute of Emory University

Yale Cancer Center

See clinicaltrials.gov

Enrollment Closed

HCRN-MEL17-309

Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma

Suthee Rapisuwon

Cancer areas:Melanoma

Columbia University Irving Medical Center

Georgetown Lombardi Comprehensive Cancer Center

MD Anderson Cancer Center

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

UC San Francisco

See clinicaltrials.gov